Last reviewed · How we verify

NCT05935969: ETGBD

ETGBD in Surgically Unfit Patients With Both Choledocholithiasis and Cholecystolithiasis

Completed Last updated 7 July 2023
What this trial tests

trial testing ERCP(Endoscopic retrograde choangiopancreatography), ETGBD(endoscopic transpapillary gallbladder drainage) in Efficacy in 302 participants. Completed in 1 May 2023.

Timeline
1 August 2022
Primary endpoint
1 March 2023
1 May 2023

Quick facts

Lead sponsorSeoul National University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment302
Start date1 August 2022
Primary completion1 March 2023
Estimated completion1 May 2023
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

20 and older, any sex, with Efficacy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cholecystectomy is recommended for patients with both gallbladder (GB) and common bile duct (CBD) stones to prevent recurrent biliary complications, unless there are specific reasons for surgery is considered inappropriate. The aim of this study was to evaluate the role of transpapillary gallbladder stent placement in surgically unfit patients with both CBD stone and gallstone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Efficacy

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05935969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing